Neurocrine biosciences reports fourth quarter and fiscal 2022 financial results and provides financial expectations for 2023

Ingrezza® (valbenazine) fourth quarter net product sales of $399 million ingrezza® (valbenazine) 2023 net product sales guidance of $1.67 - $1.77 billion enrollment complete in adult and pediatric registrational studies of crinecerfont for the treatment of congenital adrenal hyperplasia top-line data for clinical programs in congenital adrenal hyperplasia, focal onset seizure and anhedonia in major depressive disorder expected in the second half of 2023 san diego , feb. 6, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced its financial results for the fourth quarter and fiscal year ended december 31, 2022 and provided financial guidance for 2023. "we enter this year with tremendous momentum aiming to help the 7 out of 10 patients living with tardive dyskinesia in the u.s. who have not received a proper diagnosis for their uncontrollable movement disorder," said kevin gorman, ph.d.
NBIX Ratings Summary
NBIX Quant Ranking